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Signaling pathways responsible for embryogenesis play a critical
role in the maintenance of stem cells in adult life and cellular
responses to injury. Dysfunction of the developmental signaling
pathways during adult homeostasis leads to various events resulting
in the development of neoplasia. We review the biology of the
hedgehog signaling pathway and its potential role in the develop-
ment of lung cancer.
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Signaling pathways responsible for embryogenesis appearto play a critical role in the maintenance of stem cells in
adult life and cellular responses to injury. Dysregulation of
these signaling pathways during adult homeostasis can lead to
various events resulting in the development of neoplasia
(Figure 1).
Hedgehog (Hh) signaling pathway is one such pathway
that is crucial in the embryogenesis. Hh pathway also plays a
central role in the repair and regeneration of adult tissue. The
Hh signaling pathway was first studied in drosophilae. During
embryonic development, drosophilae with a mutation in the
Hh gene were covered with pointed denticles, resembling a
hedgehog, hence the name. Several studies have recently
demonstrated that dysregulation of the Hh signaling plays a
role in several cancers including the brain, skin, gastrointes-
tinal tract, pancreas, and lung.1–6
Hh SIGNALING
Mammalian Hh signaling pathway (Figure 2) consti-
tutes (a) Hh ligand with three variants: desert (Dhh), Indian
(Ihh), and sonic (Shh); (b) a transmembrane receptor-patched
homolog 1 and 2 (Ptch1 and 2); (c) smoothened (Smo), a G
protein–coupled receptor; and (d) a cytoplasmic complex that
regulates the cubitus interruptus (Ci) or glioma-associated
oncogene homolog (Gli) family of transcriptional effectors.
All the three ligands bind to the same receptors and elicit
similar responses. Shh is the most extensively characterized
variant and is widely expressed during embryogenesis. Shh
acts as a morphogen and plays an important role in the
formation of the neural tube, axial skeleton, primitive gut,
and the tracheobronchial tree.7,8
Autocatalytic cleavage and coupling of cholesterol are
the essential posttranslational processes that maintain the
signaling capability of the Hh ligands.9 The secretion of the
functional Hh ligand by the Hh-secreting cell is dependent on
the availability of dispatched (Disp), a transmembrane pro-
tein with homology to patched (Ptch), which is an Hh recep-
tor on the Hh responsive cell.10,11
The Ptch 1 and 2 are membrane receptors for Hh
ligands. Ptch 1 is more widely expressed and well charac-
terized. Binding of Hh ligand with the Ptch alters the
interactions of Ptch with Smo, resulting in the activation of
Smo. This initiates a cascade of events resulting in the Ci
and Gli entering the nucleus and acting as transcriptional
activators. It is unclear how the activation of Smo com-
municates with the cytoplasmic Ci/Gli transcription factor
complex. Gli bind to the DNA through zinc finger domains
directed to particular target genes regulating key cell
survival and differentiation functions. Gli1 is a transcrip-
tion activator, and Gli2 and Gli3 are both activators and
repressors of transcription. Gli3 and Ci regulate transcrip-
tion by binding to the CREB-binding protein, which is a
transcription coactivator. Cyclin D and cyclin E are known
transcriptional targets of Hh signaling, and these proteins
are vital in the G1-to-S transition in the cell cycle.12 Hh
signaling activates the mitosis promoting factor by in-
creasing the intranuclear availability of cyclin B.13 Hh
signaling also opposes normal stimuli for epithelial cell
cycle arrest (by inhibiting P21) and promotes cell
growth.14 Hh signaling inhibits a well-known regulator of
apoptosis, the p53 tumor suppressor gene.15
When the Hh ligand is unavailable Ptch1 inhibits the
activity of Smo, thus repressing the downstream signaling
events. When the Hh signaling is lacking, Gli proteins are
bound to microtubules in the cytosol along with a multipro-
tein complex consisting of Fused (Fu) and suppressor of Fu
(SuFu).
The Hh operates through a series of inhibitory steps.
The availability of the Hh ligand for signaling is regulated by
the expression of Hh interacting protein (HIP) on the cell
surface of Hh responsive cell. The HIP is a membrane
glycoprotein that binds to Hh ligands with an affinity similar
to that of the membrane protein Ptch1. HIP lacks signal
transduction capacity and acts to internalize and degrade the
Hh ligand.16 Activation of the Hh pathway causes an in-
creased expression of the HIP via a negative feedback mech-
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anism, thus serving as an inducible antagonist of Shh signal-
ing.16 The Hh signaling is regulated at various levels,
indicating the importance of tight control of Hh signaling.
Several inhibitors of the pathway like Ptch and HIP are
transcriptional target genes and Hh activation induces
negative feedback, reducing the intensity of Hh signaling.
Gli genes are regulated by complex mechanisms at both
the posttranslational and transcriptional level. Hh signal-
ing up-regulates Gli1 expression while repressing Gli3
expression.5
Dysregulation of the Hh signaling can occur from
ligand-dependent and -independent mechanisms (Table 1).
Hh SIGNALING IN THE DEVELOPMENT OF
NORMAL LUNG
The lungs develop from an outpouching of the prim-
itive endodermal tube into the surrounding mesenchyme.
In the developing lung in mouse models, an elevated Shh
expression was detected in the tracheal diverticulum and in
FIGURE 1. Role of developmental signaling
pathways in the Tumorigenesis.
FIGURE 2. Hedgehog signaling pathway.
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the trachea and lung endoderm.17 Studies indicate that the
Hh signaling pathway is essential for the growth and
differentiation of the trachea and lung, and aberrations in
the signaling components may be involved in abnormal
development of the lung.7,8,17 Natural teratogens like cy-
clopamine and jervine (extracted from of corn lilies) are
inhibitors of Hh signaling. Pregnant animals treated with
these inhibitors of Hh signaling at an early gestation period
results in multiple developmental anomalies including ab-
normal lung development.18
The airway epithelial progenitor (stem) cells play an
important role in the development of the respiratory epithe-
lium. The differentiation of these progenitor cells to form the
neuroendocrine or non-neuroendocrine (ciliated, mucous,
clara, or basal cells) component of the respiratory epithelium
is tightly regulated by a complex bipotential notch signal-
ing.6,19 Notch and Wnt signaling are evolutionary conserved
signaling pathways tightly regulating cell death, cell move-
ment, and cell division and differentiation during embryogen-
esis. During development and repair of the lung epithelium,
Hh signaling maintains this bipotential notch signaling.6,19
Hh and Wnt pathways possibly play an important role in the
maintenance and the expansion of the progenitor (stem) cells
during development and can mediate lung growth by signal-
ing to adjacent lung mesenchyme.20
Hh SIGNALING AND LUNG CANCER
Hh signaling is possibly inactive in the human adult
lung epithelium except in the epithelial progenitor (stem)
cells. This persistence of Hh signaling in the epithelial
progenitor (stem) cells could help maintain these cells and
play a critical role in the response to airway epithelial
injury.6,19,21 Studies on animal lung airway epithelial injury/
regeneration model suggest that persistent injury to the air-
way is a potent stimulus for the activation of the Hh signal-
ing, and this helps the expansion of airway epithelial
progenitor cells.6,19,21 Shh and Gli1 are expressed in the
regenerating lung airway epithelium.6 Studies on cell lines
showed that all the seven small cell lung cancer (SCLC) and
seven non-small cell lung cancer (NSCLC) cell lines ex-
pressed Shh protein. Five of seven SCLC cell lines expressed
both Shh and Gli1 in contrast to NSCLC, which expressed only
Shh but not Gli1.6 Analysis of clinical samples of human lung
cancer tissue demonstrated 50% (five of 10) of SCLC ex-
pressed both Shh and Gli1 compared to only 10% (four of
40) of NSCLC.6 Another study investigating the expres-
sion of Gli1 in SCLC tissue reported that 85% (34 of 40)
of SCLC express Gli1 and more than 60% have a medium
to strong expression correlating with increased Hh signal-
ing.22 It thus appears that lung cancer cells retain aspects
of the Hh signaling seen in the primitive lung endodermal
cells. However, the degree of dependence on this signaling
varies ahmong the subtypes of lung cancer. Inhibition of
Shh ligand activity using monoclonal antibody and cyclo-
pamine resulted in the significant growth inhibition in
SCLC cell lines expressing both Shh and Gli but not
NSCLC cell lines (which do not express both Shh and
Gli).6 Similar results were found in in vivo studies on lung
cancer xenografts in nude mice.6
HIP is a natural antagonist of Hh signaling as discussed
above. Reduced expression of HIP as been reported in lung
cancer A549 cell line xenograft in nude mice and a decrease
in the expression of HIP was seen in five of 10 human
NSCLC tissues.23 Experimental models studying HIP knock-
out mice confirmed increased Hh signaling.24,25 There ap-
pears to be down-regulation of HIP in endothelial cells during
angiogenesis.23 These findings suggest that reduced expres-
sion of HIP could potentially enhance the Hh signaling and
possibly facilitate angiogenesis. Hh signaling thus appears to
play a role in proliferation of malignant cells and promote
angiogenesis.
Hh SIGNALING PATHWAY AS A THERAPEUTIC
TARGET
Therapeutic inactivation of the Hh signaling offers a
potential treatment for cancer. Inactivation of the Hh
signaling can be done at various levels, mainly (1) extra-
cellular blocking of the Shh ligands using Shh antibodies,
(2) activation of Smo in the cell membrane, (3) modulating
intracytoplasmic regulators of Hh signaling like protein
kinase A and SuFu, and (4) altering the intranuclear
functioning of Gli.
Curis Inc. developed a Shh antagonist that showed
promising results in preclinical models.26,27 Antibodies to
Shh are currently being evaluated in phase I clinical trials
for basal cell carcinoma. Cyclopamine is another potential
molecule of interest for the inhibition of Hh signaling.26,27
Cyclopamine has demonstrated a good safety profile in
mice.2,4,6 Several other compounds that bind to Smo and
inhibit the downstream events have been identified
(KAAD-cyclop, SANT1-4, CUR61414).28 However, pa-
tients with downstream alterations in the Hh signaling
could be resistant to the treatment with Shh antagonist and
TABLE 1. Dysregulation of Hh Pathway in Cancer
Pathway Component Type of Cancer
Increased Hh ligand Basal cell carcinoma,1,31 medulloblastoma,
small cell lung cancer,6 digestive tract
tumors,32–34 ovarian tumors,35 prostate
cancer36
Reduced expression of Hh
interacting protein
Pancreatic cancer,37 liver,23 lung,23
digestive tract tumors,23 prostate
cancer36
Inactivating mutations in the
Ptch
Medulloblastoma,1 basal cell carcinoma,38
rhabdomyosarcoma39
Activating mutations in the
transmembrane helices of
Smo
Basal cell carcinoma,40 ovarian tumors35
Overexpression of the Gli
proteins
Basal cell carcinoma,41 small cell lung
cancer,6 esophageal cancers,33 gastric
cancers34
Loss of function mutations of
SuFu
Medulloblastoma,42 rhabdomyosarcoma,39
prostate cancer36
Hh, hedgehog; Ptch, transmembrane receptor-patched homolog; Smo, smoothened
a G protein–coupled receptor; Gli, glioma-associated oncogene homolog; SuFu, sup-
pressor of fused.
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Smo targeted therapies. Another potential mechanism for
blocking Gli activity is the use of protein kinase A agonists
like forskolin, which maintain the Gli in inactive state.29
Antisense oligonucleotides targeting Gli RNA also provide
a viable option to prevent Gli-mediated activation of target
genes.3,30
It is important to clarify the role of activation of Hh
pathway in the process of carcinogenesis and progression in
lung cancer. Numerous mechanisms have been implicated in
the development, proliferation, and progression of lung can-
cer; it is critical to understand how the Hh pathway interacts
with the other pathways implicated in lung cancer. There
have been virtually no significant advances in the systemic
therapy of SCLC in the past three decades. With the current
trend toward developing targeted therapies, the Hh pathway
modulators offer a potential new avenue in the treatment of
lung cancer.
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